A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
TransMedics Group, Inc.
TMDX
$2.8B
Mkt Cap
$72.26
+1.59%
TransMedics Group, Inc. (TMDX) has a current P/E ratio of 14.8, compared to its historical median P/E of 43.0. The stock is currently considered Cheap based on its historical valuation range.
TransMedics Group, Inc. (TMDX) has a 5-year average return on invested capital (ROIC) of 7.8%. This is below average and may indicate limited pricing power.
TransMedics Group, Inc. (TMDX) has a market capitalization of $2.5B. It is classified as a mid-cap stock.
TransMedics Group, Inc. (TMDX) does not currently pay a regular dividend.
Based on historical P/E analysis, TransMedics Group, Inc. (TMDX) appears cheap. The current P/E of 14.8 is 65% below its historical median of 43.0. The estimated fair value CAGR (P/E method) is 99.9%.
TransMedics Group, Inc. (TMDX) operates in the Electromedical & Electrotherapeutic Apparatus industry, within the Healthcare sector.
TransMedics Group, Inc. (TMDX) reported annual revenue of $605 million in its most recent fiscal year, based on SEC EDGAR filings.
We are a medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. We developed the OCS to replace a decades-old standard of care that we believe is significantly limiting access to life-saving transplant therapy for hundreds of thousands of patients worldwide. Our innovative OCS technology replicates many aspects of the organ’s natural living and functioning environment outside of the human body. As such, the OCS represents a paradigm shift that transforms organ preservation for transplantation from a static state to a dynamic environment that enables new capabilities, including organ optimization and assessment. We have also developed our NOP, an innovative turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States with a more efficient process to procure donor organs with the OCS.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 636M | 605M | 442M | 242M | 93M | 30M |
| Net Income | 172M | 190M | 35M | -25M | -36M | -44M |
| EPS | $5.02 | $4.87 | $1.01 | $-0.77 | $-1.23 | $-1.60 |
| Free Cash Flow | 151M | 134M | -81M | -165M | -58M | -32M |
| ROIC | 247.3% | 53.7% | 49.0% | -6.0% | -20.8% | -36.6% |
| Gross Margin | 59.1% | 59.9% | 59.4% | 63.8% | 69.8% | 69.9% |
| Debt/Equity | 0.12 | 0.99 | 2.01 | 3.33 | 0.36 | 0.65 |
| Dividends/Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | 94M | 109M | 37M | -29M | -31M | -39M |
| Operating Margin | 14.9% | 17.9% | 8.5% | -11.9% | -33.6% | -130.3% |
| ROE | 34.8% | 54.2% | 19.4% | -15.4% | -28.4% | -51.5% |
| Shares Outstanding | 35M | 39M | 35M | 33M | 29M | 28M |
| Metric | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 13M | 24M | 26M | 30M | 93M | 242M | 442M | 605M | 636M |
| Gross Margin | 44.1% | 58.7% | 64.9% | 69.9% | 69.8% | 63.8% | 59.4% | 59.9% | 59.1% |
| R&D | 14M | 20M | 19M | 22M | 27M | 36M | 56M | 69M | 77M |
| SG&A | 12M | 24M | 24M | 38M | 70M | 120M | 169M | 185M | 205M |
| EBIT | -20M | -30M | -26M | -39M | -31M | -29M | 37M | 109M | 94M |
| Op. Margin | -155.5% | -125.4% | -102.9% | -130.3% | -33.6% | -11.9% | 8.5% | 17.9% | 14.9% |
| Net Income | -24M | -34M | -29M | -44M | -36M | -25M | 35M | 190M | 172M |
| Net Margin | -182.5% | -142.1% | -112.1% | -146.1% | -38.8% | -10.4% | 8.0% | 31.4% | 27.0% |
| Non-Recurring | 0 | 0 | 0 | 0 | 0 | 0 | -17K | -80K | -80K |
| Returns on Capital | |||||||||
| ROIC | -48.0% | -28.1% | -25.3% | -36.6% | -20.8% | -6.0% | 49.0% | 53.7% | N/M |
| ROE | 13.2% | 48.8% | -36.3% | -51.5% | -28.4% | -15.4% | 19.4% | 54.2% | 34.8% |
| ROA | -39.3% | -45.5% | -22.3% | -30.8% | -17.6% | -5.1% | 4.7% | 20.3% | 12.0% |
| Cash Flow | |||||||||
| Op. Cash Flow | -26M | -32M | -30M | -29M | -46M | -13M | 49M | 193M | 220M |
| Free Cash Flow | -26M | -32M | -31M | -32M | -58M | -165M | -81M | 134M | 151M |
| Owner Earnings | -27M | -34M | -34M | -38M | -60M | -41M | -4.2M | 129M | 149M |
| CapEx | 418K | 165K | 455K | 3.5M | 12M | 152M | 130M | 59M | 69M |
| Maint. CapEx | 769K | 1.2M | 1.6M | 1.8M | 3.5M | 8.2M | 20M | 27M | 33M |
| Growth CapEx | 0 | 0 | 0 | 1.7M | 8.4M | 144M | 110M | 32M | 36M |
| D&A | 769K | 1.2M | 1.6M | 1.8M | 3.5M | 8.2M | 20M | 27M | 33M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | N/A | 265.9% | 30.7% | 31.3% |
| Capital Allocation | |||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 144K | 854K | 2.4M | 6.9M | 10M | 20M | 33M | 37M | 38M |
| Debt Repayment | 9.1M | 0 | 0 | 0 | 36M | 15M | 0 | 0 | 0 |
| Balance Sheet | |||||||||
| Net Debt | 704K | -47M | -91M | -49M | -134M | 62M | 122M | -19M | -421M |
| Cash & Equiv. | 20M | 20M | 25M | 26M | 201M | 395M | 337M | 489M | 480M |
| Long-Term Debt | 34M | 34M | 35M | 35M | 59M | 447M | 450M | 453M | 45M |
| Debt/Equity | -0.18 | 0.62 | 0.33 | 0.65 | 0.36 | 3.33 | 2.01 | 0.99 | 0.12 |
| Interest Coverage | -7.4 | -6.8 | -6.6 | -10.2 | -8.4 | -2.7 | 2.6 | 7.9 | 6.7 |
| Equity | -192M | 55M | 104M | 68M | 187M | 137M | 229M | 473M | 494M |
| Total Assets | 42M | 105M | 152M | 135M | 277M | 706M | 804M | 1.1B | 1.4B |
| Total Liabilities | 234M | 51M | 48M | 67M | 90M | 569M | 575M | 595M | 941M |
| Intangibles | N/A | N/A | N/A | N/A | N/A | 2.4M | 2.2M | 1.9M | 0 |
| Retained Earnings | -336M | -369M | -398M | -442M | -479M | -504M | -468M | -278M | -271M |
| Working Capital | 22M | 84M | 135M | 95M | 229M | 456M | 437M | 548M | 527M |
| Current Assets | 35M | 100M | 147M | 119M | 252M | 511M | 497M | 638M | 619M |
| Current Liabilities | 13M | 16M | 12M | 23M | 24M | 55M | 60M | 89M | 92M |
| Per Share Data | |||||||||
| EPS | -17.48 | -2.36 | -1.16 | -1.60 | -1.23 | -0.77 | 1.01 | 4.87 | 5.02 |
| Owner EPS | -19.79 | -2.42 | -1.38 | -1.36 | -2.02 | -1.26 | -0.12 | 3.30 | 4.33 |
| Book Value | -141.45 | 3.84 | 4.19 | 2.46 | 6.36 | 4.22 | 6.51 | 12.11 | 14.30 |
| Cash Flow/Share | -19.12 | -2.27 | -1.22 | -1.04 | -1.56 | -0.40 | 1.39 | 4.94 | 5.93 |
| Dividends/Share | N/A | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Shares Out. | 1.4M | 14.2M | 24.8M | 27.6M | 29.5M | 32.5M | 35.1M | 39.1M | 34.5M |
| Valuation | |||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | 60.4 | 25.5 | 14.4 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 36.3 | 16.5 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | 40.8 | 36.3 | 22.0 |
| Price/Book | N/A | 4.8 | 4.5 | 8.0 | 9.2 | 19.2 | 9.4 | 10.3 | 5.1 |
| Price/Sales | N/A | 13.7 | 15.5 | 26.0 | 11.0 | 9.3 | 9.0 | 6.8 | 3.9 |
| FCF Yield | N/A | -12.3% | -6.5% | -5.9% | -3.3% | -6.3% | -3.8% | 2.8% | 6.1% |
| Market Cap | N/A | 264M | 471M | 545M | 1.7B | 2.6B | 2.1B | 4.9B | 2.5B |
| Avg. Price | N/A | 22.70 | 16.06 | 28.50 | 34.99 | 69.33 | 112.99 | 105.27 | 72.26 |
| Year-End Price | N/A | 18.59 | 18.99 | 19.72 | 58.83 | 81.08 | 61.02 | 124.20 | 72.26 |
TransMedics Group, Inc. passes 5 of 9 quality checks, suggesting mixed fundamentals.
TransMedics Group, Inc. trades at 14.8x trailing earnings, compared to its 15-year median P/E of 43.0x, suggesting it is currently Cheap relative to its historical range. On a free-cash-flow basis, the stock trades at 18.6x vs a median of 36.3x. The company's 5-year average ROIC is 7.8% with a gross margin of 64.6%. At current prices, the estimated annualized return to fair value is +99.9%.
TransMedics Group, Inc. (TMDX) has a net profit margin of 31.4%. This is a strong margin indicating high profitability.
TransMedics Group, Inc. (TMDX) generated $134 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
TransMedics Group, Inc. (TMDX) has a debt-to-equity ratio of 0.99. This indicates moderate leverage.
TransMedics Group, Inc. (TMDX) reported earnings per share (EPS) of $4.87 in its most recent fiscal year.
TransMedics Group, Inc. (TMDX) has a return on equity (ROE) of 54.2%. This indicates the company generates strong returns for shareholders.
TransMedics Group, Inc. (TMDX) has a 5-year average gross margin of 64.6%. This high margin suggests strong pricing power and a potential competitive moat.
The Ledger Terminal provides 8 years of financial data for TransMedics Group, Inc. (TMDX), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
TransMedics Group, Inc. (TMDX) has a book value per share of $12.11, based on its most recent annual SEC filing.